Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21)

The summary for the Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21): The National Cancer Institute (NCI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Biomedical Imaging and Biotechnology (NIBIB), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) are interested in receiving grant applications that address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC) and development of animal models, novel approaches to prevent this malignancy, and therapeutic or diagnostic studies aimed at establishing reliable prognostic indicators for disease progression and/or minimizing morbidity and mortality associated with this malignancy. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -This FOA utilizes the Exploratory/Developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-05-137, which solicits applications under the NIH Research Project Grant (R01) mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations: For profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.